Pink SheetMerck ’s blockbuster cancer drug Keytruda received a one-year reprieve from selection for the Medicare price negotiation program with the enactment of Republicans’ budget reconciliation bill. The legi
ScripViking Therapeutics is continuing to advance dual GLP-1/GIP receptor agonist VK2735 on two tracks for obesity, with a pair of Phase III trials of the weekly injectable formulation under way, while a P
In VivoIn this episode of the In Vivo podcast, Jorge Santos da Silva and Matthias Bodenstedt, CEO and CFO, respectively of MoonLake Immunotherapeutics, talked through the biotech’s progress, ambition and s
ScripAstraZeneca is the latest large pharma company to announce a major manufacturing investment in the US as the Trump administration threatens to slap tariffs on imports. The drugmaker said July 21 that